Ethics & Informed Consent: Mixed-Methods Study Design (Switzerland)
A detailed academic review of the ethical submission protocol, informed consent prerequisites, and reporting standards for conducting a Mixed-Methods Study Design within the regulatory framework of Switzerland.
1. Ethical Principles & Legislative Framework
In research involving human participants, securing ethical clearance is a critical first step. For a Mixed-Methods Study Design being conducted in Switzerland, study designs must align with the primary regulatory legislation: Swiss Federal Act on Research Involving Human Beings (Human Research Act, HRA). This statutory framework ensures participant welfare, confidentiality, and voluntary involvement are protected.
National Ethics Board Clearance Pathway
In Switzerland, any research involving human diseases or the human body must be submitted to one of the regional Cantonal Ethics Committees (Kantonale Ethikkommission) via the BASEC portal. Under the Human Research Act (HRA), projects are categorised by risk categories (A, B, C). All data processing must align with the revised Federal Act on Data Protection (FADP) to ensure patient privacy and correct consent.
Administrative review and formal approval are managed by a local or regional Cantonal Ethics Committee. Researchers must secure full approval or a formal exemption certificate from this board before recruiting any participants or commencing data collection.
2. Study Design Elements & Reporting Integrity
For a Mixed-Methods Study Design, the review board places significant focus on methodological transparency. The application must outline the research rationale, recruitment protocols, inclusion and exclusion criteria, and data protection measures.
Study Classification: Minimal to Moderate Risk
Mixed designs combine survey analytics with narrative interviews. PIs must explain the data merging pipeline and protect the privacy of selected interviewees.
To guarantee academic integrity and reproducibility, the study report and subsequent publications should follow the internationally recognised reporting standard: GRAMMS framework.
Special Directive: Observational Study Protocols
As an observational or non-interventional design, the ethics board primarily focuses on data privacy, secure pseudonymisation, and informed consent. If you are conducting retrospective database research, you may apply for a waiver of consent, provided participant risk is minimised.
3. Informed Consent & Information Sheet Guidelines
A robust participant information sheet and informed consent form are critical parts of the ethical application. Ensure your documentation incorporates the following components:
Design-Specific Consent Focus Areas
Integrated consent for survey data and focus group interviews, recording agreements, and citation release clauses.
- Plain Language Explanations: Avoid complex medical or technical terminology. Ensure readability matches the general population.
- Voluntary Participation: Explicitly state that participation is entirely voluntary and that individuals can withdraw at any time without negative consequences.
- Confidentiality & Data Controls: Explain how participant data will be anonymised or pseudonymised, who will have access to it, and how long it will be securely retained under Federal Act on Data Protection (FADP).
- Risk/Benefit Disclosure: Clearly list any potential risks, discomforts, or direct benefits associated with participation in the study.
- Ethics Board Contact Information: Provide the contact details of the reviewing Cantonal Ethics Committee so participants can reach out if they have questions or concerns.
Research Ethics, Clinical Trials & Institutional Governance
Passive tracking in this Mixed-Methods Study Design in Switzerland relies on beneficence in research ethics to balance data utility with privacy. Observational registries in Switzerland must pay special attention to vulnerable populations research ethics when storing health metrics. Observational researchers must submit a secure informed consent template research form detailing electronic data pathways. Depending on the de-identification pipeline, some database studies may qualify under irb exempt research criteria. Without any animal protocols under the animal research ethics 3rs, the application focuses on human clinical data security. All records and signed consent sheets must reside on secure local servers in Switzerland to protect patient privacy and comply with national guidelines.
4. Regulatory Checklist Table
To streamline your ethical review submission, use the structured alignment checklist below:
| Requirement | Cantonal Ethics Committee Standard | GRAMMS framework Standard |
|---|---|---|
| Consent Form | Signed and dated prior to study activity. Focus: Integrated consent for survey data and focus group interviews. | Fully documented recruitment and consent paths. |
| Risk Management | Comprehensive risk mitigation plan. Storing questionnaire databases and qualitative files on distinct servers with encrypted linking tables. | Adverse events reporting strategy. |
| Data Retention | Compliance with local data protection rules (Federal Act on Data Protection (FADP)). | Provision of open-data options where possible. |
5. Academic & Research Infrastructure Matrix (Switzerland)
The following authenticated registry lists top scientific organizations, clinical laboratories, and research hospitals in Switzerland mapped via the Research Organization Registry (ROR) standards-compliance framework.
| Organization Name | Sector Type | Registry Identification |
|---|---|---|
| Trimarca (Switzerland) | company | ROR ID |
| Syndicom (Switzerland) | company | ROR ID |
| Tamedia (Switzerland) | company | ROR IDWikidata/Wiki |
| Tornos (Switzerland) | company | ROR ID |
| Velobüro (Switzerland) | company | ROR ID |
| Vischer (Switzerland) | company | ROR ID |
| Bayer (Switzerland) | company | ROR ID |
| EpiPharm (Switzerland) | company | ROR ID |
| Fulltec (Switzerland) | company | ROR ID |
| Vestergaard (Switzerland) | company | ROR IDWikidata/Wiki |
| Zambon (Switzerland) | company | ROR IDWikidata/Wiki |
| Stryker (Switzerland) | company | ROR IDWikidata/Wiki |
| CSL (Switzerland) | company | ROR IDWikidata/Wiki |
| Rommelag (Switzerland) | company | ROR ID |
| Accenture (Switzerland) | company | ROR IDWikidata/Wiki |
6. Frequently Asked Questions
How long does the review process normally take?
Review timelines depend on the volume of applications and whether your proposal qualifies for expedited review. On average, a standard review by an ethics board in Switzerland takes between 4 to 8 weeks.
Can we use digital signatures for informed consent?
Yes, digital consent forms are increasingly accepted, provided the platform used is secure, authenticates the identity of the signer, and complies with local regulations such as the eIDAS or ESIGN Act, depending on country-specific rules.
Regulatory Context
Verified Funding Bodies
Funder registries and DOI configurations verified for compliance in Switzerland via Crossref.
- Shire SwitzerlandID: 100032389 | Location: Switzerland
- Sumitomo Pharma SwitzerlandID: 100032820 | Location: Switzerland
- AgroscopeID: 501100022575 | Location: Switzerland
- Community Foundation of Switzerland CountyID: 100026553 | Location: United States
- Stratpharma SwitzerlandID: 100031486 | Location: Switzerland
- Stiftung Mercator SchweizID: 501100002331 | Location: Switzerland
- Unidistance SuisseID: 100031664 | Location: Switzerland
- Carolito StiftungID: 501100016068 | Location: Switzerland
- Agolin SwitzerlandID: 100031594 | Location: Switzerland
- Bundesamt für StrassenID: 501100003103 | Location: Switzerland
Pre-Submission Warning
Do not recruit participants or initiate study procedures before receiving official written approval from your reviewing board. Ethical approvals cannot be granted retrospectively under Swiss Federal Act on Research Involving Human Beings (Human Research Act, HRA).







